Many prostate cancer patients develop resistance to treatment called castrationresistant prostate cancer (CRPC) which is the major cause of recurrence and death. In the present study, four cyclohexanone curcumin analogs were synthesized.
| INTRODUC TI ON
Prostatectomy and radiation therapy are treatments for low-risk localized prostate cancer. However, treatment of intermediateand high-risk prostate cancer is supplemented with androgendeprivation therapy (ADT).
1 A few years after treatment, 40% of patients commonly develop recurrence called castration-resistant prostate cancer (CRPC). 1 In this state, cancer cells are not only resistant to ADT or chemotherapy but are also highly metastatic. 2 Unfortunately, chemotherapy might not provide survival benefits
for CRPC patients and may have an unacceptably high level of toxicity. 3 Therefore, finding effective non-toxic compounds that can inhibit cancer metastasis for use in clinical trials to improve survival rates among prostate cancer patients is urgently required. 4 Curcumin has been used as a food additive and in traditional medicine in many Asian countries. It has a wide range of biological activities, such as anti-inflammatory, anti-oxidative, anti-metastatic, as well as multi-drug resistance reversing properties. [5] [6] [7] Clinical trials found that curcumin does not display toxicity even at levels of up to 12 g/d. 8 However, curcumin has not yet been approved as a therapeutic agent because of its limitations, such as poor absorption, limited tissue distribution and rapid metabolism. 7 Modification of the structure of curcumin is one of the approaches used to improve the bioavailability of curcumin. Mono-carbonyl analogs of curcumin (MAC) in which the β-diketone moiety is replaced by a single carbonyl group have been synthesized and their biological properties and pharmacokinetic profiles studied. Previous studies have reported that in vitro stability and in vivo pharmacokinetic ability of MAC were higher than those of curcumin.
9
In the present study, we studied four cyclohexanone curcumin analogs in which the β-diketone moiety was replaced with a cyclohexanone group and the chemical groups on the phenolic ring were modified. We hypothesized that the analogs may provide superior anti-metastatic or anti-cancer growth abilities in androgenindependent human prostate cancer cell lines.
| MATERIAL S AND ME THODS

| Reagents
Fetal bovine serum and RPMI-1640 were purchased from Gibco BRL Company (Grand Island, NY, USA). Gelatinase A was purchased from Sigma Chemical Company (St Louis, MO, USA). Modified RIPA lysis buffer, protease inhibitor cocktail and chemiluminescent immunoblotting reagent were obtained from Thermo Fisher Scientific (Rockford, IL, USA).
| Synthesis of curcumin analogs
Curcumin and four cyclohexanone analogs were prepared as described in our previous study. Briefly after the synthesis reaction, the products were purified by recrystallization in ethanol and characterized by Fourier transform infrared spectroscopy (FTIR) and NMR. 10 Structure of curcumin and the analogs are shown in Figure 1 .
| Cells and cell culture
An androgen-independent human prostate cancer cell line (PC3)
was purchased from ATCC. The androgen-independent, androgen receptor-negative rat prostate cancer cell line (PLS10) was established in our laboratory. 11, 12 PC3 and PLS10 cells were cultured in RPMI-1640 with 10% FBS, 5 mmol/L l-glutamine, 50 IU/mL penicillin and 50 mg/mL streptomycin and maintained in a humidified incubator with an atmosphere comprising 95% air and 5% CO 2 at 37°C.
When the cells reached 70%-80% confluence, they were harvested and plated either for subsequent passages or for curcumin or its analog treatments.
| Animals
All animal experiments were carried out under protocols approved by the Institutional Animal Care and Use Committee of Nagoya City University Graduate School of Medical Sciences. Seven-week-old male BALB/c mice and 5-week-old male BALB/c-nu/nu mice were purchased from Charles River Japan Inc. (Atsugi, Japan) and housed in plastic cages with hardwood chip bedding in an air-conditioned room at 23 ± 2°C, and 55 ± 5% humidity with a 12-hour light/dark
cycle. An Oriental MF diet (Oriental MF; Oriental Yeast Co., Tokyo, Japan) and distilled water were available ad libitum. concentrations (0-100 μmol/L) of curcumin or its analogs were added.
| Cell viability assay
The cells were incubated in 5% CO 2 at 37°C for a further 48 hours. Briefly, non-heating and non-reducing samples were subjected to SDS-PAGE using a 10% acrylamide gel containing 0.1 mg/mL gelatin.
| Gelatin-zymography assay
After electrophoresis, gels were washed with 2.5% Triton-X 100 and incubated in activating buffer (50 mmol/L Tris-HCl, 200 mmol/L NaCl, 10 mmol/L CaCl 2 , pH 7.4) for 16 hours. 13 For MMP-2 and MMP-9 activities, the culture supernatant of FBS-free cultured PC3 cells was subjected to SDS-PAGE as described above. The gel was then cut into slices corresponding to each lane and placed into different tanks containing the analogs dissolved in an activating buffer and incubated for 16 hours. The gels were then stained with 0.1% Coomassie brilliant blue R and destained with 30% methanol and 10% acetic acid. Bands of gelatinolytic activity were analyzed using IMAGE J.
| In vivo pharmacokinetics
Seven-week-old male BALB/c mice were randomly divided into 
| In vivo anti-metastasis activity
Ten-week-old male BALB/c-nu/nu mice were randomly divided into Keyence, Osaka, Japan).
| In vivo anti-tumor growth activity
We first determined anti-tumor growth activity of analog 2A on 
| Western blot analysis
| Immunohistochemistry
Paraffin-embedded samples were sectioned and stained with rabbit monoclonal anti-Ki67 (SP6; Acris Antibodies GmbH, Herford, Germany) and rabbit polyclonal anti-CD31 antibodies (Abcam, Cambridge, UK) and sequentially stained with anti-rabbit secondary antibody and avidin-biotin complex. Binding complexes were then visualized with diaminobenzidine. Sections were then counterstained lightly with hematoxylin for microscopic examination.
Number of Ki67 staining cells in a minimum of 1000 cells was counted to determine the labeling index. For quantitative analysis of vessel area, CD31-positive areas per total area section were determined under microscopy (BZ-9000).
| TUNEL assay
Paraffin-embedded samples were sectioned and apoptosis determined in tumor tissue using TUNEL assay (In situ Apoptosis Detection Kit; Takara Bio Inc., Ohtsu, Japan). TUNEL assay was carried out according to the manufacturer's instructions. Number of TUNEL labeled cells in a minimum of 1000 cells was counted to determine the labeling index.
| Statistical analysis
In the in vitro experiment, experiments were carried out at least in triplicate to confirm reproducibility and presented as mean ± SD. For the in vivo experiment, data are presented as mean ± SEM. Statistical analysis was carried out with Prism version 6.0 software using a t test and one-way ANOVA, Dunnett's test or Tukey's multiple comparisons test. Significance was determined at *P < .05, **P < .01 and ***P < .001.
| RE SULTS
| Cytotoxic effects of curcumin and its cyclohexanone analogs on PC3 cells
Results showed that analogs 2A and 2F showed higher toxicity on PC3 than that of curcumin (P <0.001). IC 50 of analogs 2A and 2F were 9.00 ± 0.87 and 6.33 ± 0.76 μmol/L, respectively. Meanwhile, analogs 2I and 2J showed no cytotoxicity on PC3 as seen in 
| Effects of curcumin and its analogs on PC3 cells invasion and migration
Results showed that analogs 2F (2.5 μmol/L), 2A (5 μmol/L) and 2I
(10 μmol/L) significantly (P < .001) decreased PC3 cells invasion by 
| Effects of analogs 2A and 2F on MMP-2 and MMP-9 secretions and activities
We next examined the effects of analogs 2A and 2F on secretions of MMP-2 and MMP-9 which are the major MMP secreted from PC3 cells. It was found that analog 2A significantly decreased MMP-2 (24%) and MMP-9 (42%) secretions from PC3 cells ( Figure 3A) , whereas MMP-2 and MMP-9 secretions
were not significantly decreased by treatment with analog 2F
( Figure 3B ).
We next determined whether analogs 2A and 2F could reduce the activity of MMP-2 and MMP-9 that is secreted from PC3 cells. It was found that analogs 2A and 2F significantly decreased MMP-2 (39% and 19%, respectively) and MMP-9 (49% and 36%, respectively) activities ( Figure 3C,D) . According to the results, it could be summarized that analog 2A inhibited both MMP-2 and MMP-9 secretions and activities, whereas analog 2F inhibited MMP-2 and MMP-9 activities only, leading to a reduction in PC3 cells invasion.
| Pharmacokinetic results
Analog 2A showed the most potential anti-invasion properties; therefore, it was selected for further in vivo study. In this study, concentrations of curcumin and analog 2A in the serum after i.p.
injection were determined. Results showed that the levels of curcumin and analog 2A in the serum were not significantly different. Serum concentration of both compounds appeared mostly at the time interval after 30-60 minutes, and then rapidly declined to normal baseline within 3 hours after the injection, as shown in 
| In vitro anti-metastasis activity of analog 2A in PLS10 cells
Previous results have shown that analog 2A at a low concentration showed strong anti-metastasis potential in vitro and could be found in serum up to 3 hours after i.p. injection. We next
F I G U R E 3 Effect of analogs 2A and 2F on secretion (A,B) and activity (C,D) of MMP-2 and MMP-9 in PC3 cells. PC3 cells were incubated with increasing concentrations of analogs 2A (A) or 2F (B)
for 24 h. MMP secretion in the culture medium was then determined by gelatinzymography. For MMP activity, slab gels containing culture medium of PC3 cells were directly incubated with various concentrations of analogs 2A (C) and 2F (B) for 16 h. Level of MMP secretion and activity was quantified by IMAGE J software. Data are represented as mean ± SD of three independent experiments. * P < 0.05, **P <0.01 and ***P < .001 vs control determined the anti-metastasis effects of this compound in vivo.
The PC3 cells xenograft model presented a low incidence of metastasis; therefore, i.v. inoculation of rat-androgen-independent PLS10 cells that exerted a higher incidence of lung metastasis could be used instead. 
| In vivo anti-metastasis activity
In vivo anti-metastasis study found that body and organ (liver and kidneys) weights of curcumin-and analog 2A-treated mice were not significantly different (data not shown). Lung metastasis was 100%, whereas lymph node metastasis was found in only one mouse in the control group (1/7). Lung metastasis area of both curcumin-(P > .001) and analog 2A-(P > .01) treated mice was significantly decreased when compared to that of the control mice ( Figure 5C,D) .
From the above findings, we can summarize that both curcumin and analog 2A showed similar abilities to inhibit cancer cell metastasis in the animal model.
| Analog 2A induced cell cycle arrest and apoptosis in PLS10 cells in vitro
In 
| In vivo inhibition of tumor growth activity
In vivo anti-tumor growth study found that the average size of tumor volume in analog 2A-treated mice was significantly decreased when compared to that of the control mice. Although the tumor volume of curcumin-treated mice was also decreased, it was not significant ( Figure 7A ). Body and tumor weights of all treated mice were not found to be different when compared to the control group (Table 2 ). Microscopic observations did not find any lesions in the liver and kidneys among all mice. Immunohistochemistry staining of tumor sections showed that cell proliferation determined by Ki67 labeling index and vessel area determined by CD31 staining were significantly decreased in both the curcumin and analog 2A-treated groups ( Figure 7B,C) . Meanwhile, apoptosis examined by TUNEL assay tended to be increased in the analog 2A-treated group, but the level was not significant ( Figure 7D ).
The data suggest that curcumin and analog 2A decreased tumor volume by inhibition of cell proliferation and angiogenesis.
Additionally, analog 2A could induce apoptosis in the tumor area, which may relate to its superior anti-tumor growth effect when compared to that of curcumin.
F I G U R E 4
Level of serum curcumin and analog 2A in mice after receiving a single dose of curcumin or analog 2A (100 mg/kg) by i.p. injection. The mobile phase comprised 52% acetonitrile and 48% citric buffer. Each point is the mean ± SE of three or four mice
| D ISCUSS I ON
Curcumin has been used in clinical trials mainly for cancer but has been hampered by its poor bioavailability. 7, 17 The high reactive potential in pH values above 6.5 and the specific substrate for the reductase of β-diketone moiety resulted in the unstable condition of curcumin both in vitro and in vivo. 18 Replacement of the β-diketone moiety of curcumin with monocarbonyl provides promising pharmacokinetic profiles, improves solubility and stability and enhances selective biological activities. 19 In our previous study, we found that three of the synthetic cyclohexanone curcumin analogs, including analogs 2A, 2F and 2J, showed higher multidrug resistance-reversal properties than that of curcumin. 10 Another previous study reported that cyclohexanone curcumin analogs exerted a greater level of potency in inducing cell death and inhibiting nuclear factor kappa B (NF-κB) activity in prostate cancer cells than that of curcumin. 20 The cyclohexanone curcumin analogs also showed antioxidant and anti-inflammatory properties both in vitro and in vivo, and there was no acute toxicity after a single oral treatment (2000 mg/kg body weight).
21
The present study found that analogs 2A and 2F had greater cytotoxicity on PC3 cells than curcumin, whereas analogs 2I and 2J
showed no cytotoxicity. The findings suggest that replacement of F I G U R E 5 Anti-invasion effect of curcumin and analog 2A on PLS10 cells in vitro and in vivo. Invading (A) or migrating (B) ability of PLS10 cells was determined using transwell assay after treatment with curcumin or analog 2A for 48 h. Metastatic cells were photographed under phase-contrast microscopy and quantified by IMAGE J software. Data represent mean ± SD of three independent experiments. In the in vivo metastasis model, animals were i.p. given 30 mg/kg curcumin or analog 2A. Thirty minutes after treatment, PLS10 cells were injected into the tail vein. Mice were sacrificed at the end of week 2. Representative H&E staining of lung metastases was carried out (C). Lung metastatic foci of each group were determined using a microscope (D). Data are represented as mean ± SE of each group. **P < 0.01 and ***P < .001 vs control di-ketone with cyclohexanone, as well as modification of the chemical groups on the phenolic ring, could affect the cytotoxicity of curcumin. The hydroxy group at the R 2 position of each cyclohexanone analog could promote cytotoxicity. Moreover, analog 2F showed the strongest cytotoxicity effect, which may relate to the hydroxyl group at the R 1 position of this analog.
We found that cyclohexanone curcumin analogs 2A . Apoptotic cells were determined by Guava nexin (C) and protein expression was determined by western blot analysis. Data from a typical experiment are depicted, and similar results were obtained in three independent experiments. Level of protein expression was quantified by IMAGE J software. Data are presented as mean ± SD of three independent experiments. *P < .05, **P < .01 and ***P < .001 vs control of β-diketone with acetone improved the pharmacokinetic profile of curcumin after oral dosage of 500 mg/kg. 18 The present study found that the pharmacokinetic profile of analog 2A did not differ from curcumin, suggesting that replacement of β-diketone by the cyclohexanone group might be insufficient to address the pharmacokinetic limitations of curcumin. However, we found that lung metastasis of PLS10 cells was significantly suppressed by both curcumin and analog 2A treatment by approximately 2.5-and 1.8-fold, respectively. Although the lung metastasis area of the curcumintreated group was slightly lower than the analog 2A-treated group, it was determined to be not significant. Curcumin is rapidly metabolized to dihydrocurcumin and tetrahydrocurcumin, which have antimetastasis properties. [22] [23] [24] Metabolism of curcumin might be the one situation that promotes its anti-metastasis activity. Therefore, metabolism of analog 2A and the biological activities of analog 2A
should be further investigated.
Progression of cancer cells is a complex process, not only in terms of metastasis but also in escaping apoptosis and growth control. We found that analog 2A exerted a growth-inhibitory effect on PC3 cells (3.8-fold, P < .001) and PLS10 cells (1.7-fold, P < .01) compared to F I G U R E 7 Analog 2A treatment significantly decreased tumor volume. PLS10 cells were s.c. injected into each mouse. The mice then received treatments twice a week for 4 weeks. All mice were then sacrificed, and their tumors were removed and measured for size (A). Tumor section was carried out for immunohistochemistry of Ki67 (B), TUNEL assay (C) and CD31 (D). Data are represented as mean ± SE of each group. *P < .05 and ***P < .001 vs control logs, we found that the cyclohexanone analogs showed greater solubility in aqueous solution than did the di-ketone moiety such as curcumin. 10 Therefore, modification of the curcumin structure could assist the limitations of its solubility problem.
In conclusion, our in vitro data showed that the growth inhibitory effects of analog 2A on PC3 and PLS10 cells were more potent than that of curcumin. In the in vivo study, analog 2A showed a significant inhibitory effect on tumor volume whereas curcumin did not.
However, for proliferative markers such as Ki67 and in the TUNEL assay, the potency of analog 2A was similar to that of curcumin. For anti-metastasis studies, analog 2A showed similar effects to curcumin in in vivo examination, although analog 2A showed greater anti-invasion effects on PC3 and PLS10 cells in in vitro studies. 
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